Investing.com -- Berenberg expects the global beauty market to face slower growth in 2025, with the pace likely to fall short of L'Oréal’s projections. Amid this challenging backdrop Berenberg listed its top performers that include Beiersdorf (ETR:BEIG), Coty (NYSE:COTY), Galderma, and Unilever (LON:ULVR). Growth in developed markets is expected to cool, while China is likely to stabilize in the first half of the year before seeing a modest recovery later. Emerging markets, where companies are increasing investments, are expected to grow at a stronger pace. Berenberg upgraded Coty to Buy, expecting its upcoming investor day in June 2025 to serve as a catalyst for renewed interest. The firm expects Coty to lay out its strategy to drive sales growth, improve margins, and return more cash to shareholders. Puig was initiated at Hold due to concerns about its operational flexibility, despite its strength in the prestige segment. L’Oreal SA (EPA:OREP) was downgraded to Hold, with Berenberg noting that rising competition in mass beauty and dermatological segments could limit its market outperformance in 2025. Beiersdorf remains Berenberg’s top pick, with the firm highlighting its promising pipeline of innovative products and ongoing geographic expansion. Beiersdorf is well-positioned to outperform in a more competitive environment, thanks to its strong product launches and consistent execution. Beyond 2025, Berenberg sees risks emerging from younger, more digitally engaged consumers who are less loyal to traditional brands. By 2035, these younger cohorts, Generation Z, Alpha, and Beta, will make up half of the global workforce. While they are highly engaged with beauty products, their willingness to switch brands poses challenges for established companies, raising concerns about growth stability and brand loyalty. Another shift reshaping the industry is the rise of beauty technology. Consumers are increasingly turning to at-home beauty tech, non-invasive medispa treatments, and advanced procedures like laser and injectables. Galderma is seen as a key beneficiary due to its expertise in injectable aesthetics, while dermatological skincare is also expected to gain from this trend. However, traditional beauty categories, especially prestige products, may face longer-term risks as consumers adopt these new technologies. Berenberg expects the global beauty market to grow by 3.7% in 2025, below L'Oréal’s management forecast of 4-4.5%. Related Articles Berenberg lists top beauty stocks amid sector’s slower growth outlook Story Continues New York Attorney General urges 23andMe users to delete their data Boeing and Japan Airlines finalize order for 17 additional 737 MAX jets View Comments
Berenberg lists top beauty stocks amid sector’s slower growth outlook
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...